Allison Owings, NP
Family · Dakota Dunes, SDNPI 1417435462
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,270 of the $4,360 with a category attached, or 75.0%. 22 manufacturers reported payments, led by Abbott at 29.3% of the total. Among family clinicians in SD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 213 payments — averaging $20.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- AbbVie$1K
- Teva Pharmaceuticals USA, Inc.$548
- Lundbeck LLC$233
- Pfizer$208
- Argenx US, Inc.$153
- plus $893 from 16 others
What the payments were for
- Travel & lodging$90221%
- Food & beverage$3,27075%
- Education$1884%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 20 | $1,275 |
| AbbVie | 93 | $1,051 |
| Teva Pharmaceuticals USA, Inc. | 22 | $548 |
| Lundbeck LLC | 10 | $233 |
| Pfizer | 25 | $208 |
| Argenx US, Inc. | 6 | $153 |
| Inspire Medical Systems, Inc. | 3 | $143 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $137 |
| Lilly USA, LLC | 6 | $94 |
| Acadia Pharmaceuticals Inc | 4 | $83 |
| SK Life Science, Inc. | 4 | $80 |
| Biogen | 2 | $75 |
| AstraZeneca | 3 | $52 |
| Amneal Pharmaceuticals LLC | 2 | $41 |
| GE HealthCare | 2 | $36 |
| Neurelis, Inc. | 1 | $35 |
| Eisai Inc. | 1 | $25 |
| Impel Pharmaceuticals Inc. | 1 | $24 |
| Amgen | 1 | $19 |
| CSL Behring | 1 | $18 |
| UCB, Inc. | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INFINITY$797
- QULIPTA$124
- NURTEC ODT$116
How this compares
$4,360 in reported general payments places this provider in the 95th percentile of 588 family providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 16 | $188,636 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 23 | $187,065 |
| AubagioTeriflunomide | 14 | $129,532 |
| Avonex (4 Pack)Interferon Beta-1a | 12 | $101,055 |
| Aimovig AutoinjectorErenumab-Aooe | 120 | $96,398 |
| Nurtec OdtRimegepant Sulfate | 69 | $89,854 |
| CopaxoneGlatiramer Acetate | 12 | $83,998 |
| GlatopaGlatiramer Acetate | 27 | $47,821 |
| Lamictal XrLamotrigine | 25 | $41,790 |
| Emgality PenGalcanezumab-Gnlm | 44 | $31,638 |
| UbrelvyUbrogepant | 29 | $30,982 |
| Glatiramer Acetate | 19 | $26,620 |
| VimpatLacosamide | 26 | $25,380 |
| RytaryCarbidopa/Levodopa | 14 | $22,048 |
| KeppraLevetiracetam | 12 | $21,304 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Copaxone | $548 | $272,63428 claims |
| BiogenAvonex (4 Pack) | $75 | $101,05512 claims |
| PfizerNurtec Odt | $208 | $89,85469 claims |
| UCB, Inc.Vimpat, Briviact | $15 | $45,18050 claims |
| AbbVieUbrelvy | $1,051 | $30,98229 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide, Mycophenolate Mofetil | $41 | $26,51772 claims |
| Eisai Inc.Fycompa | $25 | $12,60321 claims |
| Neurelis, Inc.Valtoco | $35 | $9,22011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 588 family providers in South Dakota.
Other family in Dakota Dunes
- Maria AzpeitiaDakota Dunes$8K
- Nicole SheaDakota Dunes$5K
- Carey BaczwaskiDakota Dunes$4K
- Willy GarciaDakota Dunes$3K
- Brooke BuumDakota Dunes$2K
- Chad MillikanDakota Dunes$2K
- Brittany WangsnessSioux Falls$79K
- Stephanie PreisterSioux Falls$12K
- Claudia HouglandRapid City$9K
- Michelle VanhoveSioux Falls$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.